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Memory is the hallmark of the adaptive immune
system, and the observation that infectious diseases
often lead to lifelong immunity in individuals who
survive a first infection became the genesis for the
development of vaccines. Immunization, which is
the iatrogenic engineering of a protective memory
immune response to a pathogen, became a standard
part of medical care in the twentieth century, and has
had an almost incalculable positive effect on human
health and wellness. Vaccines to many, but by no
means all, infectious diseases have been developed
and are in common use. Smallpox vaccine, arguably
the most effective vaccine in human history, was
(and still is) delivered through disrupted epidermis
in a process called scarification. Virtually all vaccines
today are delivered by means of a hypodermic needle
and syringe into muscle, in a process that bypasses
the epidermis and dermis and their attendant innate
and adaptive immune attributes. This article discusses
vaccines in the context of the newly appreciated
paradigm of tissue-resident memory T cells, and
specifically discusses the role of these cells in skin
and other epithelial interfaces with the environment
in the maintenance of protective immunity.
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INTRODUCTION
Innovation is defined as ‘‘the introduction of something
new’’. Investigative dermatology, similar to all other biome-
dical scientific disciplines, depends existentially on a steady
influx of new techniques, novel approaches, new theories,
and paradigm-shifting ideas to move forward as a discipline.
Without question, our understanding of skin biology at
present is significantly different from what it was in 1937,
the year the Journal of Investigative Dermatology was first
published. This is perhaps most strikingly evident in our
current appreciation of the skin as a complex immunological
organ. This article will highlight some of the translational
innovations that have occurred during those years, particu-
larly those relevant to vaccine biology. Because a compre-
hensive review cannot be accommodated in a short article,
this manuscript reflects the authors’ personalized views.
TRANSLATIONAL IMMUNOLOGY AND INFECTIOUS
DISEASES IN THE TWENTIETH CENTURY
As America was beginning to emerge from a long economic
depression in the late 1930s, and was increasingly threatened
by international pressures that would soon lead to her entry
into World War II, translational biomedical research was
moving forward at a remarkable clip. The level of innovation
in biomedical science relevant to human disease that would
transpire in the twentieth century was nothing short of
astonishing. Hardly a family in America was not touched by
deadly childhood infectious diseases in the first few decades
of the twentieth century. Nevertheless, by mid-century,
antibiotics and vaccines had reduced morbidity and mortality
of these diseases in children by, quite literally, orders of
magnitude (Bud, 2007; Ellis, 2009). Infectious diseases, which
through millennia had profoundly shaped the course of human
history, were beginning to yield to innovations emerging
from translational discoveries in the early twentieth century.
Increasingly, bacterial diseases were beginning to respond
to recently discovered antibiotics. Pneumococcal bacterial
pneumonia, streptococcal cellulitis and pharyngitis, and
bacterial otitis media had become readily treatable diseases
(Clardy et al., 2009). By the 1950s, syphilis, an international
scourge that had helped to define the specialty of dermatology
(academic departments were often known as departments of
Dermatology and Syphilology), could for the first time be
definitively treated with penicillin (Douglas, 2009). Even
tuberculosis was beginning to yield to combination chemo-
therapeutic approaches, although this ancient enemy remains
a global challenge (Mitchison, 2005). Although certain
bacteria responsible for diseases would evolve over the next
several decades to develop antibiotic resistance, the spectrum
and impact of infectious diseases on human health was forever
altered by these new developments. However, many diseases
caused by viruses, once acquired, remained impossible to
treat definitively, and extensive research focused squarely on
prevention of these diseases rather than their treatment,
principally through innovations in vaccination.
In 1936, 1 year before the Society for Investigative
Dermatology and its journal were founded, Max Thieler
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developed a vaccine for yellow fever, an accomplishment
for which he won the Nobel prize in 1951 (Norrby, 2007).
Although primarily a disease of the tropics, deadly
yellow fever epidemics had hit Philadelphia, Baltimore,
and New Orleans in previous decades, and the prospect
of its eradication in America was enthusiastically welcomed.
The overarching rationale behind vaccination, however,
had developed centuries earlier from ancient clinical
observations, and since has been confirmed experimentally
and popularized by giants of translational medicine such
as Edward Jenner and Louis Pasteur. The principle behind
vaccination stemmed from observations that complete
and durable immunity to certain infectious diseases was
conferred to individuals by prior infection and clinical
disease. Thus, the goal of vaccination was originally to
iatrogenically create a subclinical infection, ideally with an
attenuated pathogen that did not cause disease, thus
provoking a similar protective and durable immune res-
ponse without causing a life- or health-threatening disease
(Hilleman, 2000).
However, different strategies were required for different
types of infection, based on the mechanism. When the
morbidity and mortality of an infectious disease is caused by
toxins, as is the case with tetanus, diphtheria, and pertussis
(whooping cough), generating a neutralizing antibody res-
ponse to the toxin is sufficient, although multiple booster
injections are often needed. When the disease is caused by
a viral infection of a peripheral tissue, however, the most
effective vaccines have typically involved an intact virus,
either attenuated (live but less virulent) and thus capable
of infecting host cells or rendered noninfectious by thermal
or chemical treatment (Hilleman, 2000). Measles, mumps,
and rubella vaccines are attenuated viruses, as are rota-
virus, oral polio, yellow fever, some influenza vaccines,
and varicella zoster vaccines. Relatively fewer vaccines, in
contrast, involve an inactivated virus that cannot infect
cells; these include vaccines for hepatitis A and B, seasonal
influenza, and human papilloma virus vaccines (e.g.,
Gardisil; Liu, 1998).
In fact, vaccines date back to the tenth century, and thus it
cannot be claimed that vaccination is a twenty-first (or even
twentieth) century innovation. Certainly, vaccines designed
to lower the risk of cervical cancer from human papilloma-
virus infection (i.e., papilloma virus 6, 11, 16, 18; Gardasil)
are novel, and intranasal influenza virus vaccine for influenza
(i.e., Flumist) are relatively recent developments. However,
there are still a number of diseases for which an effective
vaccine is elusive. HIV-1 is the best example, a virus whose
strategies to elude the immune system have thwarted some
of the best minds in vaccine biology (Bojak et al., 2002).
In addition, Dengue fever, Ebola, and other hemorrhagic
fevers still elude reliable vaccines. Nonviral diseases such
as malaria, tuberculosis, and third-world scourges such
as tyrpanosomiasis and leishmaniasis continue to take
enormous human tolls without a candidate vaccine in sight.
Therefore, why and how can the immune system be
apparently so readily manipulated to protect humans
against some infectious diseases, but not others? To begin
to answer these questions, it is useful to turn to a new set of
innovations, not in vaccines, but in the science of trans-
lational immunology.
ANTIBODIES ARE ONLY PART OF THE ANSWER
Virtually all vaccines developed in the past century were
tested by their capacity to generate an antibody response
(Kayhty, 1998). For pathogens that have a requisite
blood-borne phase, this is critically important. For example,
tetanus toxin must enter extracellular space and blood from
infected skin to mediate its neurological effects, and thus
circulating antibodies generated by prior vaccination can be
completely protective. Similarly, such circulating preformed
antibodies can protect against viremia or bacteremia, and
thus an antibody response is clearly important for many
diseases. However, for viral diseases such as HIV, although
antibodies may limit viremia, they cannot prevent infection
of dendritic cells and T cells at the mucosal interface
(Keating and Noble, 2003). Similarly, pathogens that have
an intercellular mode of survival, such as mycobacterium
tuberculosis, and the parasites that cause malaria and
leishmaniasis, cannot be addressed or controlled conclu-
sively by preformed antibodies. Clearly, although antibodies
have an important place in vaccine efficacy, the focused
attention on humoral response to the exclusion of cell-
mediated tissue-specific responses may be the ‘‘Achilles
heel’’ of vaccine science.
INNOVATIONS IN OUR UNDERSTANDING OF
TISSUE-SPECIFIC IMMUNITY CAN INFLUENCE VACCINE
BIOLOGY
Investigative dermatology has had a central role in clarifying
the complexity and diversity of the immune system in
peripheral epithelial tissues. For many years, the study of
immunity in skin and gut was thought to be specialized and
esoteric, and this science was often relegated to ‘‘Regional
Immunity’’ sessions at national immunology meetings. The
prevailing principle was that fundamental immunology is
really the cell biology of lymphocytes, dendritic cells, and
other cellular elements of the immune system, which could
be studied in tissue culture and were not fundamentally
dependent on any non-lymphoid anatomic context. In
retrospect, this view did not accommodate the reality that
the immune system evolved to protect the host against
microbial infection, and that challenge by such pathogens
invariably occurs at interfaces of the organism and the
environment. These epithelial barriers to the environment—
skin, gut, lung, reproductive mucosa—were precisely the
sites where the host would first encounter microbial
challenges (Kupper and Fuhlbrigge, 2004). Infectious chal-
lenges by pathogens, which cause morbidity, had to be
distinguished by the immune system from colonization by
commensal organisms, which do not. This has been most
recently highlighted by seminal work on the diversity of the
human gut and skin microbiomes (Grice et al., 2009; Tschop
et al., 2009), indicating a level of complexity in commensal
organisms that live harmoniously upon us or within us, which
had not been previously appreciated.
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Through the highly innovative work of investigative
dermatologists, skin was characterized as an organ that
contained specialized sets of dendritic cells (reviewed in
Larregina and Falo, 2005; Zaba et al., 2009; Kaplan, 2010),
specialized cells capable of activating T cells, the diversity
of which continues to be revealed. More recently, it became
clear that ‘‘memory’’ as a descriptor for T cells could refer
not only to antigenic memory but also to anatomic
memory—antigens that were first encountered through
skin, and therefore found their way to skin draining lymph
nodes, provoked an expansion of memory T cells in the
blood that expressed unique cell surface markers that not
only identified them as skin-homing T cells but also
actually helped them extravasate into skin through inter-
actions with skin microvasculature (Picker et al., 1993;
Rossiter et al., 1994; Butcher et al., 1999; Kupper and
Fuhlbrigge, 2004). Analogous populations of circulating
T cells that homed to the gastrointestinal tract were also
characterized (Butcher et al., 1999), and populations that
homed to the lung were identified as well (Purwar et al.,
2011).
Yet another level of innovation would follow. Most
recently, investigative dermatologists again made an impor-
tant and unexpected discovery: many if not most skin-homing
T cells were, in effect, ‘‘skin-resident’’ T cells, and that skin
contained far more skin-homing memory T cells at steady
state than could be found in blood (Clark et al., 2006a, b).
Similar observations were being made for gut and lung, and
resident populations of T cells were even observed in the
central nervous system after infection (Masopust et al., 2010;
Wakim et al., 2010; Purwar et al., 2011). Many of these
studies have been cross-validated in mouse models and
human tissue (Zhu et al., 2007; Gebhardt et al., 2009; Liu
et al., 2010; Masopust et al., 2010). These ‘‘tissue-resident’’
T cells, then, were enriched in specificity for pathogens
previously encountered through their respective epithelial
tissues (Clark, 2010; Bevan, 2011).
At steady state, both these T cells and the tissue-resident
dendritic cells capable of presenting antigen to them are in a
resting state. It is here that innate immunity has an important
role: cytokines produced by keratinocytes (Gutowska-Owsiak
and Ogg, 2012) and other non-bone marrow–derived resident
cells have a vital role in the generation of immune responses.
In the face of pathogenic challenge, dendritic cells activated
by the innate immune system (e.g., Toll-like receptors,
epithelial cytokines, other endogenous adjuvants; Modlin,
2011) can present pathogen/antigen to tissue-resident T
cells, thus producing a rapid T-cell effector response
that does not require memory T-cell extravasation from
peripheral blood (Sheridan and Lefrancois, 2011). These
observations have added a completely new level of impor-
tance to ‘‘regional immunology’’. Tip O’Neill was famous
for quipping that ‘‘all politics is local’’. In the same sense, it
appears that with regard to host defense against infectious
diseases, all immunology is ‘‘regional’’. Anatomical context
of immune responses is now considered central to under-
standing the pathophysiology of infectious and autoimmune
disease.
A BETTER UNDERSTANDING OF IMMUNE RESPONSES:
ANATOMIC SITE OF ANTIGEN DELIVERY MAKES A
DIFFERENCE
If tissue-resident memory T cells indeed have an important
role in host defense in epithelial tissues, then generating these
cells must be a goal of vaccination. Given what we know
about the anatomic imprinting of T cells, it stands to reason
that how and where a vaccine is delivered makes a
difference. Although injection into muscle or subcutaneous
fat may be an acceptable way to make a robust circulating
antibody response, it is not a logical way to generate
populations of relevant tissue-resident T cells. Certainly,
neither subcutaneous fat nor skeletal muscle has had to
evolve the highly sophisticated immunologic machinery to
protect against infection that peripheral epithelial tissues that
interface with the environment have had to. The observation
that the tissue, as well as the lymph node that drains the
tissue, has a role in fashioning the long-lived T-cell memory
response to infection, makes delivery into non-epithelial
tissues significantly less attractive. If the goal of vaccination is
to generate not just antibodies but also the robust and tissue-
relevant long-lasting immunity that the infectious disease
normally generates (without the morbidity and potential
mortality), how and where (anatomically) the vaccine is
delivered makes a difference. Moreover, not harnessing the
elegant and highly evolved endogenous machinery of the
skin to generate durable immunologic memory is a missed
opportunity. Indeed, a number of groups are beginning to
appreciate the fact that skin immunization has demonstrable
advantages over other routes of administration (Amorij et al.,
2010; Liu et al., 2010).
FORGOTTEN LESSONS FROM THE SMALLPOX ERA
Sometimes, it is important to get the perspectives of the oldest
person in the room. In the rush to innovate, sometimes
critical elements of existing technologies are jettisoned
because their importance is underestimated or unappre-
ciated. The smallpox vaccine is an illustrative case in point.
Smallpox, a disease caused by the poxvirus Variola major,
was quite literally one of the great scourges of humanity
(Stewart and Devlin, 2006). Civilizations rose and fell under
the pressure and sway of smallpox epidemics, and entire wars
were sometimes decided based on regional smallpox out-
breaks (Radetsky, 1999). For centuries, this highly contagious
disease decimated populations across the globe, principally
in the Eastern hemisphere, and was particularly virulent in
populations that had never been exposed previously (e.g.,
native Americans, the Western hemisphere; Eyler, 2003). It
has been proposed that the conquest of Latin and South
America by Spain could not have occurred without the
transmission, albeit unintentional, of smallpox from infected
sailors to indigenous populations. The worldwide case fatality
rate of smallpox averaged roughly 33%, and survivors were
often disfigured and/or blinded. Among infants, case fatality
ratios of 90% were common. In addition, among naive
populations in the Western hemisphere, case fatality ratios in
healthy adults of 480% were not uncommon, and native
American populations were routinely decimated by the
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disease. In the first half of the twentieth century alone, more
lives were lost to smallpox globally than were lost in both
world wars and the 1918 influenza pandemic combined. It is
therefore not an understatement that one of the greatest
achievements of modern medicine was the global eradication
of smallpox, which was finally achieved in the 1970s.
The last case in the United States of America was in 1949,
more than 10 years after the JID was first published. A
highly effective vaccine, fashioned from a related poxvirus
vaccinia virus (VACV), was responsible for this incredible
achievement.
On the basis of the observation that survivors of infection
with Variola major had subsequent lifelong immunity to
smallpox, application of fluid from a smallpox lesion to
abraded skin of a naive recipient was first recorded in the
tenth century in China. This process, know as ‘‘variolation’’,
predictably led to full-blown protective immunity, but more
than occasionally led to clinical infection and sometimes
death from smallpox. Variolation, sometimes just known as
inoculation, fell in and out of favor over the next several
centuries after its use spread to other continents, and was
practiced sporadically in many countries. Its use in Britain
and other European countries was championed by Lady
Montague, who learned of the practice while living in Turkey
in the eighteenth century. However, despite a fatality rate of
2–3% from variolation, its success in protecting against
smallpox (with a case fatality rate of 20–30%) could not be
ignored (Cantey, 2011). In 1797, Edward Jenner VACV used
the contents of a cowpox blister, derived from the infected
hand of a milkmaid, and applied it to the disrupted epidermis
of a young boy (i.e., vaccination). The boy experienced mild
illness, but recovered completely. Further, in an experiment
that would not pass institutional review board muster today,
Jenner challenged the young boy by inoculation with Variola
major (Bloch, 1993). The boy did not contract smallpox,
either locally or systemically, and Jenner concluded that
protection was complete. In a striking example of innovation
not being appreciated by established science, Jenner’s
manuscript describing the experiment to the Royal Society
of Medicine in London was summarily rejected without
review. He privately published a booklet describing the
experiment and the theory behind it (Gross and Sepkowitz,
1998), but it took a number of years for vaccination to be
accepted as a novel and highly effective protective therapy
for this deadly disease. It should be noted that neither Lady
Montague nor Edward Jenner, nor other proponents of
inoculation and vaccination, had any knowledge of viruses,
least of all the significant genetic homology between the
different poxvirus species.
VACV would be subsequently isolated, cultured, titrated,
and purified in the next two centuries, but its mode of
delivery to human subjects remained largely unchanged.
In the era before hypodermic syringes, the virus was applied
to skin abraded by multiple strokes of a bifurcated needle,
a process known as ‘‘scarification’’. Indeed, the stability of
virus preparations, and the relative ease by which nonmedi-
cally trained volunteers could vaccinate recipients by
scarification even in remote third-world settings, facilitated
the global WHO-led vaccination strategy that led to the first
eradication of a human infectious disease (Parrino and
Graham, 2006). Even today, when laboratory workers must
work with poxviruses during experiments, the vaccine used is
delivered by scarification.
Although vaccination with VACV was much safer than
variolation, it was not without risk, and patients with
compromised immune systems, as well as atopic dermatitis,
occasionally suffered complications leading to morbidity and
sometimes mortality (Wollenberg and Engler, 2004). Thus,
after the eradication of smallpox in the wild, the risk–benefit
ratio of smallpox vaccination was considered to have
reached a tipping point, and routine vaccination of all
children in the United States of America was discontinued in
the 1980s. Even with the threat of bioterrorism looming after
the anthrax attacks of 2001, this decision to not universally
vaccinate the public was reinforced in the absence of a clear
and present danger of smallpox infection (Parrino and
Graham, 2006).
Demonstrably safer replication-deficient VACVs, includ-
ing modified VACV Ankara (MVA), have been used to
vaccinate large populations in European countries (Kennedy
and Greenberg, 2009). This virus is used at a dose 100 times
greater than the dose of VACV used in scarification, and is
delivered intramuscularly. Although it engenders a robust
antibody response, the T-cell response to MVA is less well
characterized, and its ability to protect against smallpox is
(thankfully) largely hypothetical. Because of the ease through
which poxviruses can be manipulated through molecular
cloning, and because poxvirus vectors can accommodate
large ‘‘payloads’’ of complementary DNAs encoding for
antigens, their use as vaccines for other infectious diseases
and cancers is being pursued. However, in virtually all of
the extant or proposed applications, the VACV vectors are
proposed to be delivered by means of a hypodermic syringe.
Indeed, in the era of the hypodermic syringe, the practice of
scarification to deliver poxviruses has been increasingly
viewed as a quaint and unnecessary relic of the history of
medicine.
A careful review of the history of smallpox vaccination,
however, would challenge this view. When hypodermic
injection of VACV was directly compared with scarification,
the latter was superior as judged both by surrogate immuno-
logical measures of vaccine efficiency and immunity to
smallpox itself. In fact, the presence of a ‘‘pox’’ lesion, which
we now understand as the result of epidermal keratinocyte
infection with VACV and the attendant immune response,
was strictly correlated with immunity to smallpox (Koplan
and Marton, 1975). This was never achieved with hypo-
dermic injection, except when virus-containing fluid was
accidentally injected into the perforated epidermis upon
needle withdrawal (Koplan and Marton, 1975). In mouse
models, it was shown very recently that skin scarification was
orders of magnitude more effective at inducing a protective
T-cell–mediated immune response when directly compared
with intradermal, subcutaneous, intramuscular, or even
intraperitoneal delivery of VACV. This was true not only for
wild-type VACV but also for the replication-deficient MVA
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(Liu et al., 2010). Although antibody responses were robust,
the greatest differences were seen in protective T-cell–
mediated responses, particularly in skin and lung (Liu et al.,
2010).
Additional studies showed how these uniquely protective
T-cell responses were generated. Shortly after skin scarifica-
tion with VACV, T cells proliferated in draining lymph nodes,
but then differentiated and separated into two groups. One
group acquired skin-homing markers, entered the blood, and
then migrated into skin, where they could remain in situ long
term (Liu et al., 2006). The other group did not upregulate
skin-homing markers, but rather retained markers of central
memory T cells. These T cells entered blood and circulated
into distant lymph nodes. The majority of these central
memory T cells continued to recirculate between blood and
multiple lymph nodes, but some acquired secondary tissue-
specific imprinting; for example, T cells entering mesenteric
nodes would acquire a4b7 and migrate to gut epithelium (Liu
et al., 2006). Thus, scarification would generate different
subset populations of T cells that would, respectively, enter
the skin first, but also circulate between blood and lymph
nodes, as well as entering distant epithelial tissues to become
resident memory T cells. In fact, T cells generated by scari-
fication that enter lung epithelium and remain in situ provide
significant protection against a lethal respiratory challenge in
the mouse model of VACV infection (Liu et al., 2010).
NEW DEVELOPMENTS
It is increasingly being appreciated that vaccination through
skin has advantages over intramuscular or subcutaneous
routes (Amorij et al., 2010; Liu et al., 2010). For example,
experimental flu vaccines are being delivered through
skin with good success, as judged by antibody responses
(interestingly, T-cell responses are rarely monitored; Amorij
et al., 2010). Delivery without hypodermic needle injection
requires breaching the formidable stratum corneum, and
whether this feat is achieved by ultrasound approaches
(Lavon and Kost, 2004), microneedle patches (Sullivan et al.,
2010), or nanoneedles, considerable attention is being paid
to delivery of vaccine across the top layer of skin, the
epidermis, into the dendritic cell–rich dermis below. Most
modern vaccines in development, however, focus on protein
antigens or virus-like particles delivered with an adjuvant
to activate the innate immune system. Whether any of
these approaches can ever approximate the success of live
attenuated virus is unknown. It may be that when a virus
infects a target cell, even if it cannot replicate, a series of
events occurs that cannot be reproduced or even approxi-
mated by introduction of antigen with adjuvants, even when
the latter are directed at Toll-like receptors or other
components of the innate immune system. Further optimiza-
tion of nonviral vector vaccination will answer this question
more definitively.
Vaccines to HIV have met with near-universal failure,
despite a huge investment of resources, time, and intellectual
energy (Girard et al., 2011). Most efforts against HIV, as
against most pathogens, have focused on the antibody
response, and particularly on antigens that are rarely, if ever,
mutated as this wily virus adapts to the host (Girard et al.,
2011). The bias of an adherent to the concept of resident
memory T-cell immunity (your author) is that although
circulating antibodies are important, having a population of
tissue-resident effector memory T cells present in the tissue
that is being infected, whether reproductive or gastrointest-
inal mucosa, is essential for durable and effective immunity.
Very recently, a report was published indicating that a
vaccine focused specifically on generating effector memory
T cells was highly effective in protecting monkeys against
the closely related SIV virus (Hansen et al., 2011). The senior
author of this paper, Louis Picker, is famous within
Investigative Dermatology for discovering that the HECA-
452 antibody bound preferentially to T cells in skin; he
coined the term ‘‘cutaneous lymphocyte antigen’’ (Picker
et al., 1990). It is encouraging to see the T-cell perspective
making innovative forays into the world of vaccine biology.
FUTURE DIRECTIONS
New hypotheses are being proposed about the true role of
tissue-resident memory T cells. These hypotheses have in
common the view that immune memory must contain central
and peripheral elements to be successful (Clark, 2010; Bevan,
2011). The peripheral elements are dendritic cells and other
antigen-presenting cells coexisting with populations of T cells
that are, for all intents and purposes, resident to epithelial
tissues that interface with the environment, including the
skin. These resident T-cell populations are poised to rapidly
respond to pathogens that attempt to breach the epithelium of
skin, lung, gut, or reproductive mucosa. The central elements
of immune memory include circulating central memory
T cells, which are enriched for the same antigenic specifi-
cities as tissue-resident memory T cells. These cells can
provide a second wave of immune response to support the
first wave provided by tissue-resident T cells. They can also
provide help to antibody-producing memory B cells. Finally,
B cells themselves are important mediators of the immune
response, as their ability to produce antibodies is an
important defense against systemic spread of the localized
epithelial infection. B cells can also very efficiently present
antigen to T cells, and thus their potential interplay cannot be
ignored. To ignore any of these elements of the immune
system while developing a vaccine strategy is unlikely to
meet with full success. The intersection of vaccine biology
and modern immunology is an exciting and fertile substrate
for further translational innovation.
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